Kornimate/medical-research-clean huggingface dataset:
methods of etiological diagnosis of cerebral amyloid angiopathy

Conditions: Cerebral Amyloid Angiopathy; Intracerebral Hemorrhage

Summary: the purpose of this study is to 1. early identify patients based on clinical manifestation, imaging, gene and histology, explore diagnostic tools 2. get gene repertoire of chinese 3. build a cerebral amyloid angiopathy (caa) prospective cohorts, observing the disease history, and exploring prognostic factors of hemorrhage in caa patients

we recruited consecutive patients with intracerebral hemorrhage(ich). clinical data and the results of laboratory tests and ct will be assessed and recorded. all the subjects will get gene tests including many genes related with aβ and small vessel disease (next-generation sequencing and target enrichment system) . the result of the mri scans including cerebral microbleeds(cmbs)、cortical superficial siderosis（css）, white matter change(wmc) and enlarged perivascular spaces (epvs) will be assessed using scales. ocular fundus exams such as funduscopy and imaging will be used to assess multiple dot and blot hemorrhages and microaneurysms by ophthalmologist. mini-mental state examination(mmse) will be used to assess the cognitive function. patients who need operation on the hematoma for the treatment will accept a brain tissue pathological exams according to this, a prospective cohort of caa patients based on clinical manifestation, imaging, gene and histology will be built, and diagnostic tools such as gene and mri results, etc will be explored. and we will get gene repertoire of chinese patient with ich. then, the subjects will be followed up on 30-day, 3-month, 6-month, and 1-year.the patients' clinical outcome will be assessed , and the results of laboratory tests and therapy will be recorded. prognostic factors of patients with caa related ich will be explored.

Eligibility criteria:
inclusion criteria: ①diagnosed wiht spontaneous cerebral hemorrhage after the head ct. ② the patients and their family members agreed to participate in this study. exclusion criteria: ①cerebral hemorrhage caused by traumatic, cerebral infarction, tumor and arteriovenous malformation. ②patients who can not provide reliable information or are considered unsuitable for the study.
pranayama and deep breathing exercises sleep quality after laparoscopic cholecystectomy

Conditions: Cholecystectomy, Laparoscopic

Summary: this study explores the impact of pranayama and deep breathing exercises on alleviating shoulder pain and improving sleep quality following laparoscopic cholecystectomy.

the data were collected by the researcher by face-to-face interview method at sbu van training and research hospital general surgery clinics. necessary information was given to healthcare professionals in the clinics where the research would be conducted, and the lists of patients who would undergo surgery were followed. data collection started in the preoperative period, and the data collection phase ended when the patient was discharged after the surgery. to collect pranayama, deep breathing and control group data, the researcher identified patients who were scheduled to undergo laparoscopic cholecystectomy surgery in general surgery services on a daily basis and met the sampling criteria. in the hospital where the research was conducted, laparoscopic cholecystectomy surgeries were performed excluding emergency surgeries. it is performed electively and patient education is provided on the day of surgery. patients are taken into surgery according to the surgery list determined the day before. it was determined by randomization whether the patients participating in the study would be in the control or experimental groups. patients were included in the study according to randomization order. patients coming for surgery were randomly assigned to a pranayama group, a deep breathing group, and a control group. this randomization technique was continued until the sample number in the research groups was reached, and the study was terminated when 22 patients were included in the pranayama group, 22 in the deep breathing group and 22 in the control group.

Eligibility criteria:
inclusion criteria: * shoulder pain after elective laparoscopic cholecystectomy surgery patients, * no hearing-speech problems that would hinder communication, * no cognitive-mental problems, * not having any psychiatric disease, * no sleep disorder * patients who have not previously attended courses on breathing exercises and yoga, * all volunteers who agreed to participate in the study were included in the study. exclusion criteria: * admitted to the intensive care unit in the early postoperative period, * extra surgical intervention (hernia repair, etc.), * during laparoscopic cholecystectomy, patients undergoing open cholecystectomy patients were excluded from the study.

Keywords: pranayama, shoulder pain, sleep quality
(cost-)effectiveness of slimmer diabetes prevention intervention

Conditions: Diabetes Mellitus Type 2

Summary: the overall aim of the project is to evaluate the (cost-)effectiveness of the slimmer diabetes prevention intervention in dutch primary health care.

this is a randomised controlled trial, conducted in a real-life setting (dutch primary health care).

Eligibility criteria:
inclusion criteria: * age 40-70 years * impaired fasting glucose (ifg; i.e. venous plasma glucose concentration ≥6.1 and ≤6.9 mmol/l) during the past 5 years, according to the gp registration database or diabetes risk score ≥7 as calculated from the diabetes risk test * willing and able to participate in the intervention for at least 1.5 years * dutch speaking exclusion criteria: * known diabetes mellitus * any chronic illness that makes 1.5-years survival improbable, interferes with glucose tolerance, or makes participation in a lifestyle intervention impossible * patients with any severe cardiovascular disease (this also includes history of cardiac dysrhythmia), unless gp gives agreement * medication known to interfere with glucose tolerance * any mental or physical disability that will hinder participation in the lifestyle intervention * severe psychiatric disease * patients who showed bad compliance in the past * participation in another regular vigorous exercise and/or diet programme, i.e.: * intensive exercise programme: any exercise programme offered by a physiotherapist and/or patients sporting at least 3 times a week at their own initiative. * intensive diet programme: patients who visited a dietician at least 3 times during the last year.

Keywords: prevention combined lifestyle intervention primary health care
dexmedetomidine vs fentanyl on time to extubation in patients undergoing laparoscopic sleeve gastrectomy

Conditions: Dexmedetomidine; Fentanyl; Time to Extubation; Morbid Obesity; Laparoscopic Sleeve Gastrectomy

Summary: this study aims to compare the efficacy of dexmedetomidine versus fentanyl during general anesthesia for patients with morbid obesity undergoing laparoscopic sleeve gastrectomy.

the use of opioids in surgeries for patients with morbid obesity is controversial since they are known for having ventilatory depressing effects. therefore, alternative analgesics are needed to improve anesthetic management for patients with obesity.

Eligibility criteria:
inclusion criteria: * age from 20 to 50 years old. * both sexes. * american standards association (asa) physical status ii - iii. * body mass index (bmi) ≥ 35 kg/m2. exclusion criteria: * allergy to α2 -adrenergic agonist. * history of cardiac disease (uncontrolled hypertensive patient with blood pressure above 140/90, implanted pacemaker, poor cardiac function (ejection fraction\< 50%), history of myocardial infarction, cerebral stroke, transient ischemic attack, or coronary artery disease with or without stents. * neuromuscular disease, liver disease (coagulopathy inr\>1.5 or platelet count \ 1.2mg/dl, serum k \>5.5mmol/l). * opioid medication within 24 hours before the operation. * respiratory diseases as copd, uncontrolled asthmatic patients.
development of a specific measure for assessing adherence in adult patients with hemophilia.

Conditions: Haemophilia

Summary: research project for the development, construction and validation of a questionnaire of adherence to treatment in adult patients with hemophilia. it aims to build a scale according to five relevant dimensions of adherence to treatment: 1) physician-patient relationship, 2) knowledge of the disease, 3) previous bleeding problems, 4) knowledge of future consequences and difficulties, and 5) benefits of treatment.

* descriptive study for the construction of a multidimensional scale of adherence to treatment in adult patients with hemophilia. * validation of a scale specific measure for patients with hemophilia that includes 5 dimensions that may affect adherence to treatment: a) the doctor-patient, b) regarding knowledge of the disease, c) the previous hemorrhages, d) knowledge future sequels, e) difficulties with treatment. * statistical and psychometric analysis of the adherence questionnaire for adult patients with hemophilia. * description of the theoretical framework that justifies the completion of the questionnaire, and the choice of the dimensions and items that make up the measurement scale. * the questionnaire obtained in this project will identify the actual degree of patient adherence to multidisciplinary treatment, taking as gold standard, compliance with pharmacological treatment (the difference between the treatment prescribed and consumed).

Eligibility criteria:
inclusion criteria: * patients diagnosed with hemophilia a or b. * patients over 18 years of age. exclusion criteria: * patients with neurological or cognitive impairments that hinder oral and written comprehension. * patients who have not signed the informed consent document

Keywords: haemophilia adherence of treatment knowledge of illness medical-patient relationship illness behavior treatment difficulties.
berzosertib human mass balance study (ddriver solid tumors 208)

Conditions: Advanced Solid Tumor

Summary: the study was conducted in two periods, period 1 (mass balance) and period 2 (extension). the purpose of period 1 of this study was to provide a quantitative characterization of the mass balance, rates and routes of elimination, and metabolic pathways after a single intravenous administration of \[14c\]berzosertib. the purpose of period 2 was to assess safety and efficacy of berzosertib in combination with topotecan.


Eligibility criteria:
inclusion criteria: . * histologically proven advanced solid tumors that are considered appropriate for treatment in period 2 of this study, for which no effective standard therapy exists, or standard therapy has failed or cannot be tolerated * eastern cooperative oncology group performance status (ecog ps) =\< 1 * evaluable disease according to response evaluation criteria in solid tumors version 1.1 (recist 1.1) at screening * participant has adequate renal, hematological and hepatic function * other protocol defined inclusion criteria could apply exclusion criteria: * participants with uncontrolled intercurrent illness including, but not limited to, severe active infection including, acute respiratory syndrome coronavirus-2 infection/coronavirus disease 2019 (covid 19), immune deficiencies, uncontrolled diabetes, uncontrolled arterial hypertension and symptomatic congestive heart failure * concurrent participation in another interventional clinical study is not permitted. * known hypersensitivity to the study interventions, a similar structural compound, or to one or more excipients used * prior or concurrent treatment with a nonpermitted drug/intervention from the first dose of study intervention administration, as defined per protocol. * other protocol defined exclusion criteria could apply

Keywords: topotecan ataxia telangiectasia mutated and rad3-related (atr) protein atr inhibitor m6620 berzosertib mass balance
effects of oral magnesium supplementation on patients with type 2 diabetes

Conditions: Type2 Diabetes

Summary: a total of 74 adult patients with type 2 diabetes mellitus (t2d) will be enrolled and randomized into 2 groups. the intervention group will receive oral magnesium (mg) supplementation. the study objectives are: 1. to estimate level of mg (total and ionized) in patient with type 2 dm. 2. to determine the effect of mg supplementation for diabetic patient on serum mg level, glycemic control and level of inflammation. 3. to assess the correlation between serum mg level and glycemic control and level of inflammatory mediators (crp)

a total of 74 adult patients of both genders who had been diagnosed with t2d and are on oral anti-hyperglycemic drug and their hba1c between 7and 8 %, will be enrolled in the study. initially the study protocol will be explained \& informed written consent will be obtained from all participants. all subjects will be evaluated to ensure that they meet the eligibility criteria through: full history taking, complete physical examination and investigations. the intervention group will receive oral magnesium (mg) supplementation for 3 months (250 mg of elemental magnesium daily). the primary outcome is to determine the effect of mg supplementation for diabetic patient on serum mg level, glycemic control and level of inflammation.

Eligibility criteria:
inclusion criteria: * patients with type 2 diabetes with hba1c between 7 and 8%. * both genders will be included in this study. exclusion criteria: * patients on insulin. * patients on diuretics or angiotensin-converting enzyme inhibitors in the last 2 weeks. * patients taking mg containing supplements within 3 months. * patients with significant gastrointestinal disorders (eg, chronic diarrhea). * patients with impaired renal functions (egfr\< 60 ml/min). * heart block or heart failure * patients treated with aldosterone antagonists. * pregnant patients * patients with evidence of infection. * patients with chronic inflammatory conditions eg, sle

Keywords: oral magnesium type 2 diabetes diabetes control hba1c inflammation
assessment of safety distance of far-infrared therapeutic device to human skin

Conditions: Far- Infrared Burn

Summary: abstract the equipment "infrared therapeutic device" is widely used in various medical institutions in taiwan. the infrared therapeutic device improves the blood circulation, relieves muscle stiffness and pain by the heat energy radiated by the infrared light, and has a significant relief effect on patients with joint pain, muscle soreness, and back discomfort. however, the principle of the infrared therapeutic device is thermal energy, and there is no complete literature on the parameters such as treatment intensity and time and the full distance. in addition, the literature on the damage that can be caused is not based on clinical evidence, and there is no standardization study on the use of equipment, so it is hoped that this test will explore the safety distance of infrared therapeutic devices. the project is expected to recruit 50 people from 20 years old to 75 years old in the chinese medicine clinic of tainan hospital of the ministry of health and welfare, which is included in the diagnosis of osteoarthritis, degenerative arthritis, osteoporosis and other related chinese medicine clinics. in patients with diseases, the main complaint must include patients with lower back pain and back pain. subjects should exclude diseases that may be affected by chemoradiotherapy, cardiovascular disease, anemia, hypertension, etc., and exclude dermatitis, skin irritation, and erythema. skin diseases such as lupus. the test site is the tcm clinic of tainan hospital of the ministry of health and welfare. the air conditioner is fixed at a constant temperature of 28 degrees. the output power is calculated by the wattage meter, and the distance and temperature of the infrared lamp are measured. finally, the appropriate temperature and distance of the infrared lamp to the human skin are estimated through calculation. keywords: infrared, far- infrared, burn


Eligibility criteria:
inclusion criteria: * healthy adults over the age of 20 are not excluded from patients with lower back pain. exclusion criteria: 1. exclude cardiovascular diseases, anemia, high blood pressure and other diseases that may affect circulation. 2. people with skin diseases, skin allergies, and skin abnormalities. 3. patients who are clinically diagnosed with cancer or other major injuries. 4. excluded conditions are alcoholics, diabetic patients (blood sugar greater than or equal to 200 mg/dl), and severe or life-threatening complications (determined by the trial host based on medical history). 5. women who are pregnant or breastfeeding (positive urine pregnancy test). 6. the moderator decides that it is not suitable to participate in this research.
capnographic monitoring of propofol-sedation during colonoscopy

Conditions: Hypoxia

Summary: the present study is a randomized, prospective, single-blinded study. patients presenting for colonoscopy under sedation will be included according to the statistical sample size calculation. patients will be randomized to either group 1- capnographic monitoring or group 2- oxygenic monitoring during propofol-based sedation for colonoscopy. episodes of hypoxia are documented and compared in both groups.


Eligibility criteria:
inclusion criteria: * indication for colonoscopy * patient wishing sedation during colonoscopy * ≥ 18 years of age * signed informed consent form exclusion criteria: * diseases which preclude study accomplishment or put the patient at any risk (e.g. psychiatric diseases) * non-contractually capable persons * pregnancy * lactation
a study of a long-acting r-factor 7a (factor viia) in adult men with hemophilia a or b

Conditions: Hemophilia A; Hemophilia B

Summary: the purpose of the current phase 1/2a single dose, dose-escalating study is to evaluate the acute safety, pharmacokinetics (pk) and pharmacodynamics (pd) properties of mod-5014 in adult subjects with moderate/severe congenital hemophilia a or b. this will be a single-dose, open label, dose-escalating study. each dose cohort will be concluded by a safety review, following which escalation to the next dose cohort will be approved.


Eligibility criteria:
inclusion criteria: * diagnosis of moderate or severe congenital hemophilia a or b with or without inhibitors exclusion criteria: * diagnosis of any coagulation disorder other than hemophilia a or b * receipt of any immunomodulatory therapy within 3 months prior to screening, with the exception of hepatitis c or hiv therapy * have had, within one month prior to study drug administration, a major surgical procedure (e.g. orthopedic, abdominal) or have an elective surgery planned within the study period * use of any anticoagulant for arterial/venous obstructions and/or atrial fibrillation within 7 days prior to first study drug administration * malignancy within past 5 years (excluding non-melanoma skin cancer)

Keywords: hemophilia factor vii factor viia inhibitors long acting
cancer within a pandemic: a telemental health intervention

Conditions: Cancer; Survivorship; Depression, Anxiety

Summary: the purpose of this research study is to test an online support group designed to help young adults who have had cancer treatment to manage their mood during a pandemic. investigators hope to learn more about what effects a support group may have upon the health and well-being of young adults who have undergone cancer treatment by offering an online support group that teaches healthy coping skills in a practical and acceptable way. investigators would also like to know if certain parts of the online material is more effective in helping subjects manage their mood.

primary objective: to improve self-efficacy for young adult cancer survivors navigating pandemic conditions. secondary objective: to reduce depression and anxiety levels through meaning-making.

Eligibility criteria:
inclusion criteria: * documented cancer diagnosis within the wake forest baptist medical center medical record; * outpatient cancer survivor (diagnosis, treatment, or post-treatment); * aged 18-39 * must speak english * must have computer with audio and visual capabilities. * must live within north carolina * must have experienced health-related anxiety and/or distress in last 3 months. exclusion criteria: * exclusion criteria will be determined by pre-screening data and medical chart reviews * active inpatient hospitalization * major cognitive impairment, marked concerns with working memory, concentration, or word finding difficulties that significantly impairs daily functioning documented in most recent clinic note or self-reported * recent suicide attempt(s), psychiatric hospitalization, or psychotic processing (last 3 years) * bipolar disorder (i or ii) diagnosis, as evidenced by an icd-10 code within the past year or revealed during subject interview * moderate to severe alcohol or drug abuse; as evidenced by an icd-10 codes related to alcohol or illicit substance abuse in the medical record within the past year or revealed during subject interview. * severe eating disorders; as evidenced by an icd-10 code in the medical record such as anorexia nervosa or bulimia within the past year or revealed during patient interview * repeated "acute" crises for example: repeated acute crises consisting of marked psychological distress that impairs function and warrants clinician intervention (e.g., occurring once a month or more frequently); this we be evaluated by the clinician screener.

Keywords: telemental intervention